To determine whether TFF3 mediates acquired trastuzumab resistance in HER2+/ER+ breast cancer, trastuzumab resistant BT474 and MDA-MB-361 cells were generated (Figures 4A and 5A) [60]. Here, ERBB2 is linked to breast cancer.